Spectral Diagnostics (OTCMKTS:EDTXF) Posts Quarterly Earnings Results, Hits Estimates

Key Points

• Spectral Diagnostics reported quarterly earnings of ($0.01) per share, matching Wall Street’s consensus estimate.
• The stock rose 0.8% on Friday to $1.03, with trading volume above its average.
• The company focuses on developing and commercializing products for septic shock treatment, including diagnostic and therapeutic tools such as the Endotoxin Activity Assay and Polymyxin B Hemoperfusion device.

Spectral Diagnostics (OTCMKTS:EDTXF - Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01), Zacks reports.

Spectral Diagnostics Stock Up 0.8%

OTCMKTS EDTXF traded up $0.01 on Friday, hitting $1.03. The company's stock had a trading volume of 13,337 shares, compared to its average volume of 7,337. Spectral Diagnostics has a 1-year low of $0.58 and a 1-year high of $1.31. The company's 50-day moving average is $0.99 and its 200 day moving average is $0.99. The firm has a market cap of $301.64 million, a PE ratio of -8.57 and a beta of 0.09.

About Spectral Diagnostics

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.